UnknownNot Applicable

AMH Predicts Postchemotherapy Menopause in Premenopausal Breast Cancer Patients

153 participantsStarted 2024-03-15

Plain-language summary

To determine the accuracy of AMH postchemotherapy in predicting permanent menopause after chemotherapy in breast cancer patients who did not use OFS before menopause

Who can participate

Age range40 Years – 59 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age over 40(include 40 years old), or before 60, female
✓. Primary invasive breast cancer diagnosed by histopathology, except of occult breast cancer, inflammatory breast cancer and Paget's disease
✓. Operable patients with no distant metastases at diagnosis (stage T1-T3, any N, M0)
✓. The patient was at premenopausal status when first diagnosed (had menstruation in the last 12 months or hormone levels not reached menopause when diagnosed, E2 \> 30ng/L, FSH≤30U/L)
✓. The patient has used chemotherapy (neoadjuvant chemotherapy or adjuvant chemotherapy) after diagnosis

Exclusion criteria

✕. Age before 40, or over 60(include 60 years old)
✕. Patient who accepted bilateral ovariectomy or ovarian radiotherapy
✕. Patient who used gonadotropin-releasing hormone agonist ( GnRHa)
✕. Stage IV (metastatic) breast cancer
✕. The patient was at postmenopausal status when first diagnosed (no menstruation in the past 12 months or hormone levels reached menopause when diagnosed, E2≤30ng/L, FSH \> 30U/L)
✕. The patient has not used chemotherapy (neoadjuvant or adjuvant chemotherapy) since diagnosis
✕. The investigator determines that the patient has any other condition that make her unfit to participate in the study

What they're measuring

Anti-Mullerian Hormone

Timeframe: Before chemotherapy, within a week after last chemotherapy, 1,3,6,12,18,24 months after chemotherapy

Trial details

NCT IDNCT06313476

SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-04-30

View on ClinicalTrials.gov More Breast Cancer trials